On February 9, Huadong Medicine Co.Ltd(000963) (000963) announced that the wholly-owned subsidiary, Sino US East China, had reached an exclusive strategic cooperation with American akso biopharmaceutical, Huadong Medicine Co.Ltd(000963) with a total amount of no more than US $75 million, including down payment and milestone payment for clinical development, registration and sales, Obtain the exclusive clinical development and commercialization rights of its global innovative drug AB002 (for solid tumor treatment) in the Asia Pacific region (except Japan). Huadong Medicine Co.Ltd(000963) will guide the clinical trial application through the joint research committee and akso.
It is understood that akso is a global biopharmaceutical company with innovative and comprehensive therapies in the treatment of cancer, autoimmune diseases and genetic diseases. AB002 is a double target fusion protein targeting PD-L1 / L2 and IL15 in preclinical stage, including a deep technology platform engineering mutant soluble PD-1 (for immune checkpoint inhibition) and an IL-15 agonist (for activating NK cells). Its main technology and patent authorization come from Stanford University. AB002 can capture PD-L1 and PD-L2 with ultra-high binding affinity and target IL-15 agonists to tumor cells. Its ability to accurately target tumor cells avoids the activation of systemic NK cells and prolongs the half-life of IL-15 agonists.
AB002 can inhibit immune checkpoints and activate natural killer cells (NK cells) to treat solid tumors. Dr. Liu Dongzhou, chief scientific officer of Huadong Medicine Co.Ltd(000963) said that AB002 has great potential in cancer immunotherapy. This cooperation further enriches the Huadong Medicine Co.Ltd(000963) innovative tumor product pipeline, Huadong Medicine Co.Ltd(000963) will work closely with akso to accelerate the development of AB002 and benefit the majority of cancer patients by using its own clinical development and registration ability.
The tumor field is the strategic field of Huadong Medicine Co.Ltd(000963) key layout. Huadong Medicine Co.Ltd(000963) has many years of experience in the development and industrialization of tumor drugs, and has a variety of listed anti-tumor products. In recent years, Huadong Medicine Co.Ltd(000963) has continuously focused on the differentiated layout in the field of cancer. Taking clinical needs and patients as the first, it has successively cooperated with a series of innovative R & D enterprises at home and abroad with advanced technology, such as American immunogen company, prevention bio company, ashvattha company, norling biology and so on.
Recently, Huadong Medicine Co.Ltd(000963) is the world’s first target for folate receptors α (FR α) The results of the American key single arm clinical trial (Soraya trial) of mirvetuximab, an ADC drug under development for positive ovarian cancer, have reached the main end point, which will have a positive impact on the registration and application of the product in China. At present, the PK pharmacokinetic study of phase I clinical trial in China has been completed, and the first subject has been enrolled and administered.
At the same time, this strategic cooperation will further expand the innovative drug R & D pipeline of Huadong Medicine Co.Ltd(000963) , give full play to the advantages of Huadong Medicine Co.Ltd(000963) in clinical development, registration and commercialization, and help the company deepen the layout of global innovation R & D track. Under the guidance of the comprehensive innovation transformation strategy, Huadong Medicine Co.Ltd(000963) innovative drug R & D has entered a rapid development channel, and more and more new drug R & D pipelines are gradually emerging. At present, the company has a global layout of innovative drugs in the three core treatment fields of anti-tumor, endocrine and autoimmunity.
Since the comprehensive innovation and transformation, Huadong Medicine Co.Ltd(000963) has taken innovative drugs as the basis and direction for building future core competitiveness, focused and focused on the development of innovative drugs and high-tech wall generic drugs with outstanding clinical value in the fields of major and chronic diseases such as anti-tumor, endocrine and autoimmune diseases, and closely followed the gene therapy of biological drugs outside China The technological development and R & D trends in frontier fields such as antibody drugs form a differentiated layout based on the unmet clinical needs.
In the future, Huadong Medicine Co.Ltd(000963) will continue to pay attention to the potential unmet clinical treatment needs, continue to increase the layout in the field of innovative drugs, constantly enrich the innovative R & D pipeline, improve the accessibility of drugs, constantly create the differentiated competitive advantage of the company’s product pipeline, and strive to achieve excellent market competitiveness and international layout in the field of innovative drugs.
